tiprankstipranks
Silence Therapeutics Plc (SLN)
NASDAQ:SLN
US Market
SLN
Silence Therapeutics
RESEARCH TOOLSreports
Want to see SLN full AI Analyst Report?

Silence Therapeutics (SLN) Stock Forecast & Price Target

392 Followers
See the Price Targets and Ratings of:

SLN Analyst Ratings

Moderate Buy
6Ratings
Moderate Buy
5 Buy
0 Hold
1 Sell
Based on 6 analysts giving stock ratings to
Silence
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

SLN Stock 12 Month Forecast

Average Price Target

$37.00
▲(235.75% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Silence Therapeutics in the last 3 months. The average price target is $37.00 with a high forecast of $75.00 and a low forecast of $4.00. The average price target represents a 235.75% change from the last price of $11.02.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","76":"$76","21.25":"$21.3","39.5":"$39.5","57.75":"$57.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$75.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$37.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,21.25,39.5,57.75,76],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.49,15.452307692307693,20.414615384615388,25.376923076923077,30.339230769230774,35.30153846153846,40.26384615384616,45.226153846153856,50.188461538461546,55.150769230769235,60.11307692307693,65.07538461538462,70.03769230769231,{"y":75,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.49,12.52923076923077,14.568461538461538,16.607692307692307,18.646923076923077,20.686153846153847,22.725384615384613,24.764615384615382,26.803846153846152,28.84307692307692,30.88230769230769,32.92153846153846,34.96076923076923,{"y":37,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.49,9.990769230769232,9.491538461538461,8.992307692307692,8.493076923076924,7.993846153846154,7.4946153846153845,6.995384615384616,6.496153846153846,5.996923076923077,5.497692307692308,4.998461538461538,4.499230769230769,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.17,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.77,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.1,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.16,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.59,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.08,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.9,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.98,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.47,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.13,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.53,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.5,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.49,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$75.00Average Price Target$37.00Lowest Price Target$4.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Chardan Capital Analyst forecast on SLN
Keay Nakae
Chardan Capital
Chardan Capital
―
Buy
―
Reiterated
08/16/26
Analysts Offer Insights on Healthcare Companies: Silence Therapeutics (NASDAQ: SLN), Cardinal Health (NYSE: CAH) and Allogene Therapeutics (NASDAQ: ALLO)
H.C. Wainwright Analyst forecast on SLN
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$75
Buy
580.58%
Upside
Reiterated
08/14/26
Analysts Offer Insights on Healthcare Companies: Jade Biosciences (NASDAQ: JBIO), Silence Therapeutics (NASDAQ: SLN) and Vertex Pharmaceuticals (NASDAQ: VRTX)
Morgan Stanley Analyst forecast on SLN
Michael Ulz
Morgan Stanley
Morgan Stanley
$25→$32
Buy
190.38%
Upside
Assigned
08/11/26
Silence Therapeutics (SLN) Receives a Buy from Morgan Stanley
William Blair Analyst forecast on SLN
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
08/10/26
Analysts Are Bullish on Top Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Silence Therapeutics (SLN)
Goldman Sachs Analyst forecast on SLN
Richard Law CFA
Goldman Sachs
Goldman Sachs
$4
Sell
-63.70%
Downside
Reiterated
07/27/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Vericel (NASDAQ: VCEL) and Silence Therapeutics (NASDAQ: SLN)
Cantor Fitzgerald Analyst forecast on SLN
Prakhar Agrawal
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Initiated
06/24/26
Silence Therapeutics initiated with an Overweight at Cantor FitzgeraldSilence Therapeutics initiated with an Overweight at Cantor Fitzgerald
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Chardan Capital Analyst forecast on SLN
Keay Nakae
Chardan Capital
Chardan Capital
―
Buy
―
Reiterated
08/16/26
Analysts Offer Insights on Healthcare Companies: Silence Therapeutics (NASDAQ: SLN), Cardinal Health (NYSE: CAH) and Allogene Therapeutics (NASDAQ: ALLO)
H.C. Wainwright Analyst forecast on SLN
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$75
Buy
580.58%
Upside
Reiterated
08/14/26
Analysts Offer Insights on Healthcare Companies: Jade Biosciences (NASDAQ: JBIO), Silence Therapeutics (NASDAQ: SLN) and Vertex Pharmaceuticals (NASDAQ: VRTX)
Morgan Stanley Analyst forecast on SLN
Michael Ulz
Morgan Stanley
Morgan Stanley
$25→$32
Buy
190.38%
Upside
Assigned
08/11/26
Silence Therapeutics (SLN) Receives a Buy from Morgan Stanley
William Blair Analyst forecast on SLN
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
08/10/26
Analysts Are Bullish on Top Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Silence Therapeutics (SLN)
Goldman Sachs Analyst forecast on SLN
Richard Law CFA
Goldman Sachs
Goldman Sachs
$4
Sell
-63.70%
Downside
Reiterated
07/27/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Vericel (NASDAQ: VCEL) and Silence Therapeutics (NASDAQ: SLN)
Cantor Fitzgerald Analyst forecast on SLN
Prakhar Agrawal
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Initiated
06/24/26
Silence Therapeutics initiated with an Overweight at Cantor FitzgeraldSilence Therapeutics initiated with an Overweight at Cantor Fitzgerald
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Silence Therapeutics

3 Months
Myles MinterWilliam Blair
Success Rate
13/20 ratings generated profit
65%
Average Return
+15.77%
Copying Myles Minter's trades and holding each position for 3 Months would result in 65.00% of your transactions generating a profit, with an average return of +15.77% per trade.
1 Year
Myles MinterWilliam Blair
Success Rate
13/20 ratings generated profit
65%
Average Return
+30.69%
Copying Myles Minter's trades and holding each position for 1 Year would result in 65.00% of your transactions generating a profit, with an average return of +30.69% per trade.
2 Years
Patrick TrucchioH.C. Wainwright
Success Rate
17/21 ratings generated profit
81%
Average Return
+99.78%
Copying Patrick Trucchio's trades and holding each position for 2 Years would result in 80.95% of your transactions generating a profit, with an average return of +99.78% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SLN Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
6
10
10
8
6
Buy
2
3
3
3
4
Hold
0
0
0
0
0
Sell
1
1
0
0
0
Strong Sell
0
0
0
1
1
total
9
14
13
12
11
In the current month, SLN has received 10 Buy Ratings, 0 Hold Ratings, and 1 Sell Ratings. SLN average Analyst price target in the past 3 months is 37.00.
Each month's total comprises the sum of three months' worth of ratings.

SLN Financial Forecast

SLN Earnings Forecast

Next quarter’s earnings estimate for SLN is -$0.12 with a range of -$0.28 to -$0.07. The previous quarter’s EPS was -$0.09. SLN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year SLN has Performed in-line its overall industry.
Next quarter’s earnings estimate for SLN is -$0.12 with a range of -$0.28 to -$0.07. The previous quarter’s EPS was -$0.09. SLN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year SLN has Performed in-line its overall industry.

SLN Sales Forecast

Next quarter’s sales forecast for SLN is $124.00K with a range of $0.00 to $400.00K. The previous quarter’s sales results were $0.00. SLN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year SLN has Performed in-line its overall industry.
Next quarter’s sales forecast for SLN is $124.00K with a range of $0.00 to $400.00K. The previous quarter’s sales results were $0.00. SLN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year SLN has Performed in-line its overall industry.

SLN Stock Forecast FAQ

What is SLN’s average 12-month price target, according to analysts?
Based on analyst ratings, Silence Therapeutics Plc’s 12-month average price target is 37.00.
    What is SLN’s upside potential, based on the analysts’ average price target?
    Silence Therapeutics Plc has 235.75% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is SLN a Buy, Sell or Hold?
          Silence Therapeutics Plc has a consensus rating of Moderate Buy which is based on 5 buy ratings, 0 hold ratings and 1 sell ratings.
            What is Silence Therapeutics Plc’s price target?
            The average price target for Silence Therapeutics Plc is 37.00. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $75.00 ,the lowest forecast is $4.00. The average price target represents 235.75% Increase from the current price of $11.02.
              What do analysts say about Silence Therapeutics Plc?
              Silence Therapeutics Plc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of SLN?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.